# EDGAR Filing Document

**Accession Number:** 0001786255
**File Stem:** 0001256071-23-000002
**Filing Date:** 2023-2
**Character Count:** 3551
**Document Hash:** 4337a71f9c0342fad65c8efb3022173f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001256071-23-000002.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001256071-23-000002

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Icosavax, Inc.
- **CENTRAL INDEX KEY:** 0001786255
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92771
- **FILM NUMBER:** 23601899

**BUSINESS ADDRESS:**
- **STREET 1:** 1930 BOREN AVE., SUITE 1000
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98101
- **BUSINESS PHONE:** (206) 737-0085

**MAIL ADDRESS:**
- **STREET 1:** 1930 BOREN AVE., SUITE 1000
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98101
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLATINUM INVESTMENT MANAGEMENT LTD
- **CENTRAL INDEX KEY:** 0001256071
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** C/O PLATINUM ASSET MANAGEMENT
- **STREET 2:** LEVEL 8, 7 MACQUARIE PLACE
- **CITY:** SYDNEY AUSTRALIA 2000
- **STATE:** C3
- **ZIP:** 00000
- **BUSINESS PHONE:** 61292557533

**MAIL ADDRESS:**
- **STREET 1:** C/O PLATINUM ASSET MANAGEMENT
- **STREET 2:** LEVEL 8, 7 MACQUARIE PLACE
- **CITY:** SYDNEY AUSTRALIA 2000
- **STATE:** C3
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PLATINUM ASSET MANAGEMENT LTD
- **DATE OF NAME CHANGE:** 20030722

```

Schedule 13G

Name of issuer: Icosavax, Inc.

	Title of class of securities: Common Stock

	Cusip: 45114M109

	Date of event which requires filing: 12/31/2022

	Rule 13d-1(b)

	1.	Platinum Investment Management Limited

	2.	(b)

	3.

	4.	Sydney Australia

	5.	Platinum Investment Management Limited
		2,095,181 	(5.25%)
		Note:Combined total of underlying managed funds

	6.	N/A

	7.	Platinum Investment Management Limited
		2,249,711 	(5.64%)
		Note:Combined total of underlying managed funds

	8.	N/A

	9.	2,249,711

	10.	No

	11.	5.64%

	12.	IA

Item 1.

(a) 	Icosavax, Inc.

(b)     1930 BOREN AVE.
	SUITE 1000
	SEATTLE,
	WA 98101
	USA

Item 2.

(a) Platinum Investment Management Limited

(b) Level 8, 7 Macquarie Place
    Sydney NSW 2000
    Australia
(c) Australia
(d) Common Stock
(e) 45114M109

Item 3.
(e) An IA in accordance with Section 240.13d-1(b)(1)(ii)(e)

Item 4.

(a) 2,249,711
(b) 5.64%
(c) (i) 2,095,181
(ii) 0
(iii) 2,249,711
(iv) 0

Item 5
No

Item 6
The clients of Platinum Investment Management Ltd including pooled
investment vehicles and other managed accounts have the right to
receive or power to direct the receipt of dividends from, and the
proceeds from the sale of, Icosavax, Inc.

Item 7
N/A

Item 8
N/A

Item 9
N/A

Item 10
(a) By signing below, I certify that to the best of my knowledge and
belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
(b) N/A

After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information
set forth in this statement is true, complete and correct.

```